Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects - Zhang, Qin; Sun, Cheng; Wu, Jinying; Wu, Juan; Zhang, Xuan; Liu, Yueyue; Dou, Changlin; Qin, Huilin; Zhang, Qian; Zhou, Renpeng; Hu, Wei (Expert opinion on biological therapy, 2023)
Keywords: Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - metabolism; Biosimilar Pharmaceuticals - pharmacokinetics; Cardiovascular Agents - adverse effects; Cardiovascular Agents - pharmacokinetics; Double-Blind Method; East Asian People; Glucagon-Like Peptide-1 Receptor Agonists - adverse effects; Glucagon-Like Peptide-1 Receptor Agonists - pharmacokinetics; Glucagon-Like Peptides - analogs & derivatives; Healthy Volunteers; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacokinetics; Immunoglobulin Fc Fragments - adverse effects; Immunoglobulin Fc Fragments - pharmacology; Male; Therapeutic Equivalency; Dulaglutide; safety; bioequivalence; immunogenicity; biosimilar; pharmacokinetic similarity